Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Novo Cure Limited Announces Retirement of Director Timothy Scannell
PUBLIC · NVCRSep 09, 2026•about 2 hours ago
Position
Director
Company
Novocure
Timothy Scannell
ZugBiotechnologyHealth CareMedicalTherapeutics
Description
NovoCure Limited has announced that Timothy Scannell has retired from his position as a director on the company's Board effective September 2, 2026. His retirement comes after five years of service and was not due to any disagreement with the company or its management. The company appreciates his contributions during his tenure
Company Information
Company
Novocure
Location
Zug, Zug, Switzerland
About
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Don't miss Novocure's next move
Get an email the moment Novocure changes its leadership, hires an exec, or expands, usually minutes after it happens.
ZugBiotechnologyHealth CareMedicalTherapeutics